These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30713370)

  • 41. Comparison of four MRI protocols for detection of extrahepatic colorectal cancer metastases.
    Sivesgaard K; Jöhnk ML; Larsen LP; Sørensen M; Kramer S; Løgager VB; Hansen F; Pedersen EM
    J Magn Reson Imaging; 2017 Dec; 46(6):1619-1630. PubMed ID: 28301099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT.
    Kumar J; Seith A; Kumar A; Sharma R; Bakhshi S; Kumar R; Agarwala S
    Pediatr Radiol; 2008 Sep; 38(9):953-62. PubMed ID: 18636251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of gadolinium injection on diffusion-weighted imaging with background body signal suppression (DWIBS) imaging of breast lesions.
    Moschetta M; Telegrafo M; Rella L; Stabile Ianora AA; Angelelli G
    Magn Reson Imaging; 2014 Dec; 32(10):1242-6. PubMed ID: 25127984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility of diffusion-weighted imaging with DWIBS in staging Hodgkin lymphoma in pediatric patients: comparison with PET/CT.
    Baranska D; Matera K; Podgorski M; Gorska-Chrzastek M; Krajewska K; Trelinska J; Grzelak P
    MAGMA; 2019 Jun; 32(3):381-390. PubMed ID: 30498885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
    Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
    Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unenhanced breast MRI (STIR, T2-weighted TSE, DWIBS): An accurate and alternative strategy for detecting and differentiating breast lesions.
    Telegrafo M; Rella L; Stabile Ianora AA; Angelelli G; Moschetta M
    Magn Reson Imaging; 2015 Oct; 33(8):951-5. PubMed ID: 26117691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Whole body MRI with qualitative and quantitative analysis of DWI for assessment of bone marrow involvement in lymphoma.
    Balbo-Mussetto A; Saviolo C; Fornari A; Gottardi D; Petracchini M; Macera A; Lario CV; Gallo T; Tarella C; Cirillo S
    Radiol Med; 2017 Aug; 122(8):623-632. PubMed ID: 28421406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial.
    Mesguich C; Hulin C; Latrabe V; Asselineau J; Bordenave L; Perez P; Hindie E; Marit G
    JMIR Res Protoc; 2020 Sep; 9(9):e17850. PubMed ID: 32909953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
    Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
    Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
    Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.
    Hempel JM; Kloeckner R; Krick S; Pinto Dos Santos D; Schadmand-Fischer S; Boeßert P; Bisdas S; Weber MM; Fottner C; Musholt TJ; Schreckenberger M; Miederer M
    Cancer Imaging; 2016 Nov; 16(1):37. PubMed ID: 27809936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
    Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
    BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.